ANTX Projected Dividend Yield
AN2 Therapeutics Inc ( NASDAQ : ANTX )AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. 20 YEAR PERFORMANCE RESULTS |
ANTX Dividend History Detail ANTX Dividend News ANTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |